Drug General Information
Drug ID
D0Y1UL
Former ID
DNC010328
Drug Name
(E)-3-(4-hydroxybenzylidene)indolin-2-one
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530673]
Structure
Download
2D MOL

3D MOL

Formula
C15H11NO2
Canonical SMILES
C1=CC=C2C(=C1)C(=CC3=CC=C(C=C3)O)C(=O)N2
InChI
1S/C15H11NO2/c17-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)16-15(13)18/h1-9,17H,(H,16,18)/b13-9+
InChIKey
PLAOAGFXNCEZMZ-UKTHLTGXSA-N
PubChem Compound ID
Target and Pathway
Target(s) Proto-oncogene tyrosine-protein kinase receptor ret Target Info Inhibitor [530673]
KEGG Pathway Endocytosis
Pathways in cancer
Thyroid cancer
Central carbon metabolism in cancer
Pathway Interaction Database Signaling events regulated by Ret tyrosine kinase
Posttranslational regulation of adherens junction stability and dissassembly
WikiPathways SIDS Susceptibility Pathways
Dopaminergic Neurogenesis
References
Ref 530673Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. Epub 2010 Jan 11.Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.
Ref 530673Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. Epub 2010 Jan 11.Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.